Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Theracryf Plc
TCFCurrent price
0.7 GBX
+0.011 GBX (+1.61%)
Last closed
0.7 GBX
Company
theracryf.com
ISIN
unknown
Sector
Healthcare
Industry
Biotechnology
Exchange
London Exchange
Capitalization
2 991 013 GBX
Yield for 12 month
-68.18 %
1Y
3Y
5Y
10Y
15Y
TCF
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom. Address: Alderley Park, Nether Alderley, United Kingdom, SK10 4TG
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
835.18 GBXP/E ratio
–Dividend Yield
–Current Year
+39 594 593 GBX
Last Year
+44 194 014 GBX
Current Quarter
–
Last Quarter
+39 594 593 GBX
Current Year
+38 494 811 GBX
Last Year
+42 894 168 GBX
Current Quarter
-499 970 GBX
Last Quarter
+38 994 705 GBX
Key Figures TCF
1 year
3 years
5 years
10 years
EBITDA
-3 554 533 GBX
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-48.26 %
PEG Ratio
–
Return On Equity TTM
-81.67 %
Wall Street Target Price
835.18 GBX
Revenue TTM
395 946 GBX
Book Value
0.009 GBX
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100 %
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-0.01 GBX
Diluted Eps TTM
-0.01 GBX
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics TCF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History TCF
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1164:1147
Payout Ratio
–
Last Split Date
12.02.2021
Dividend Date
–
Stock Valuation TCF
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
2.4935
Price Sales TTM
7.5541
Enterprise Value EBITDA
0.324
Price Book MRQ
1.2778
Financials TCF
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators TCF
For 52 weeks
0.59 GBX
2.5 GBX
50 Day MA
0.74 GBX
Shares Short Prior Month
–
200 Day MA
1.01 GBX
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart